Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands

Gynecologic Oncology

Volumn 125, Issue 3, 2012, Pages 649-654

  Van Altena, Anne M ^a   Karim Kos, Henrike E ^b   De Vries, Esther ^b,c   Kruitwagen, Roy F P M ^d,e   Massuger, Leon F A G ^a   Kiemeney, Lambertus A ^a,f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Eindhoven   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f Netherlands Comprehensive Cancer Organisation The Netherlands   (Netherlands)

Author keywords

Adjuvant chemotherapy; Ovarian cancer; Surgery; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NETHERLANDS; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREND STUDY;

ADULT; AGE FACTORS; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NETHERLANDS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84861187808     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.02.033     Document Type: Conference Paper

References (42)

1. Website Netherlands Cancer Registration http://www.iknl.nl/page.php?id= 3164&nav-id=298 2009
2. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
3. F. Vernooij, P. Heintz, E. Witteveen, and G.Y. van der The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review Gynecol Oncol 105 2007 801 812
4. B.A. duBois, J. Rochon, J. Pfisterer, and W.J. Hoskins Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review Gynecol Oncol 112 2009 422 436
5. H.R. Balvert-Locht, J.W. Coebergh, and W.C. Hop Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study Gynecol Oncol 42 1991 3 8
6. A. Fritz, C. Percy, A. Jack, K. Shanmugaratnam, L. Sobin, and D.M. Parkin International Classification of Diseases for Oncology 3rd 2000 World Health Organization Geneva
7. C. Wittekind, F.L. Green, R.P.V. Hutten, M. Klimpfinger, and L.H. Sobin TNM Atlas 5th ed 2005 Springer-Verlag Berlin
8. A. Heintz, F. Odicino, and P. Maisonneuve Carcinoma of the ovary Int J Gynaecol Obstet 95 Suppl. 1 2006 S161 S192
9. L.J. Schouten, P. Hoppener, P.A. van den Brandt, J.A. Knottnerus, and J.J. Jager Completeness of cancer registration in Limburg, The Netherlands Int J Epidemiol 22 1993 369 376
10. F. Ederer, and H. Heise Instructions to IBM 650 programmers in processing survival computations 1959 National Cancer Institute Bethesda MD
11. H. Brenner, and O. Gefeller An alternative approach to monitoring cancer patient survival Cancer 78 1996 2004 2010
12. P.W. Dickman, A. Sloggett, M. Hills, and T. Hakulinen Regression models for relative survival Stat Med 23 2004 51 64
13. T. Bjorge, A. Engeland, S. Hansen, and C.G. Trope Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993 Int J Cancer 75 1998 663 670
14. A. Klint, L. Tryggvadottir, and F. Bray Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964-2003 followed up to the end of 2006 Acta Oncol 49 2010 632 643
15. J.S. Barnholtz-Sloan, A.G. Schwartz, F. Qureshi, S. Jacques, J. Malone, and A.R. Munkarah Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades Am J Obstet Gynecol 89 2003 1120 1127
16. H. Brenner, C. Stegmaier, and H. Ziegler Trends in survival of patients with ovarian cancer in Saarland, Germany, 1976-1995 J Cancer Res Clin Oncol 125 1999 109 113
17. J. Engel, R. Eckel, and G. Schubert-Fritschle Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate Eur J Cancer 38 2002 2435 2445
18. L. Minelli, F. Stracci, S. Prandini, I.F. Moffa, and R.F. La Gynaecological cancers in Umbria (Italy): trends of incidence, mortality and survival, 1978-1998 Eur J Obstet Gynecol Reprod Biol 115 2004 59 65
19. C.G. Hannibal, R. Cortes, G. Engholm, and S.K. Kjaer Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002 Acta Obstet Gynecol Scand 87 2008 1353 1360
20. C.L. Laurvick, J.B. Semmens, C.D. Holman, and Y.C. Leung Ovarian cancer in Western Australia (1982-98): incidence, mortality and survival Aust N Z J Public Health 27 2003 588 595
21. J.K. Chan, M.K. Cheung, and A. Husain Patterns and progress in ovarian cancer over 14 years Obstet Gynecol 108 2006 521 528
22. H.E. Karim-Kos, de VE, I. Soerjomataram, V. Lemmens, S. Siesling, and J.W. Coebergh Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s Eur J Cancer 44 2008 1345 1389
23. N. Akhtar-Danesh, L. Elit, and A. Lytwyn Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992-2005: a population-based study Gynecol Oncol 123 2011 192 195
24. M.D. Chirlaque, D. Salmeron, and E. Ardanaz Cancer survival in Spain: estimate for nine major cancers Ann Oncol 21 Suppl. 3 2010 iii21 iii29
25. M.P. Coleman, D. Forman, and H. Bryant Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data Lancet 377 2011 127 138
26. J.P. Neijt, W.W. ten Bokkel Huinink, and M.E. van der Burg Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma Lancet 2 1984 594 600
27. G. Omura, J.A. Blessing, and C.E. Ehrlich A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study Cancer 57 1986 1725 1730
28. E.R. Greimel, V. Bjelic-Radisic, J. Pfisterer, F. Hilpert, F. Daghofer, and B.A. duBois Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel J Clin Oncol 24 2006 579 586
29. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
30. A. Covens, M. Carey, P. Bryson, S. Verma, Kee F.M. Fung, and M. Johnston Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer Gynecol Oncol 85 2002 71 80
31. M.J. Engelen, H.E. Kos, and P.H. Willemse Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma Cancer 106 2006 589 598
32. A.R. Feinstein, D.M. Sosin, and C.K. Wells The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer N Engl J Med 312 1985 1604 1608
33. R.C. Bast Jr., D. Badgwell, and Z. Lu New tumor markers: CA125 and beyond Int J Gynecol Cancer 15 Suppl. 3 2005 274 281
34. D. Badgwell, and R.C. Bast Jr. Early detection of ovarian cancer Dis Markers 23 2007 397 410
35. A.N. Rosenthal, U. Menon, and I.J. Jacobs Screening for ovarian cancer Clin Obstet Gynecol 49 2006 433 447
36. S.S. Buys, E. Partridge, and A. Black Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial JAMA 305 2011 2295 2303
37. A.L. Oei, L.F. Massuger, J. Bulten, M.J. Ligtenberg, N. Hoogerbrugge, and J.A. de Hullu Surveillance of women at high risk for hereditary ovarian cancer is inefficient Br J Cancer 94 2006 814 819
38. A. Finch, M. Beiner, and J. Lubinski Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation JAMA 296 2006 185 192
39. T. Thigpen, M.F. Brady, and G.A. Omura Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience Cancer 71 1993 606 614
40. L.R. Duska, Y.C. Chang, and C.E. Flynn Epithelial ovarian carcinoma in the reproductive age group Cancer 85 1999 2623 2629
41. H.A. Maas, R.F. Kruitwagen, V.E. Lemmens, S.H. Goey, and M.L. Janssen-Heijnen The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study Gynecol Oncol 97 2005 104 109
42. H. Brenner, E. Steliarova-Foucher, and V. Arndt Up-to-date monitoring of childhood cancer long-term survival in Europe: methodology and application to all forms of cancer combined Ann Oncol 18 2007 1561 1568